The relationship between EGFR gene mutation and the expressions of ERCC1 and RRM1 proteins in stages I-III lung adenocarcinoma tissues
10.3781/j.issn.1000-7431.2013.03.009
- Author:
Chuan-Shan YAO
1
Author Information
1. Department of Oncology
- Publication Type:Journal Article
- Keywords:
Excision repair crosscomplementation group 1;
Lung neoplasms;
Mutation;
Receptor epidermal growth factor;
Ribonucleotide reductase subunit M1
- From:
Tumor
2013;33(3):258-263
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the relationship between the mutation of EGFR (epidermal growth factor receptor) gene and the expressions of ERCC1 (excision repair cross-complementation group 1) and RRM1 (ribonucleotide reductase M1) proteins in adenocarcinoma tissues from patients with stages I-III lung adenocarcinoma. Methods: The status of EGFR gene mutation in exons 19 and 21 in adenocarcinoma tissues from 99 patients with stages I-III lung adenocarcinoma was detected by amplification refractory mutation system using fluorescence-based quantitative-PCR instrument. The expressions of ERCC1 and RRM1 proteins were detected by immunohistochemistry. Results: The mutation rate of EGFR gene in all patients was 46.5%. The females or the non-smokers had a higher mutation rate of EGFR gene (P < 0.05). A high expression level of ERCC1 protein was found in 50.5% of patients (50/99), and a high expression level of RRM1 protein was also found in 52.5% of patients (52/99). A low expression level of ERCC1 protein was more likely to be seen in patients with EGFR mutation as compared with the patients without EGFR mutation (P = 0.035), but there was no significant relationship between EGFR mutation and the expression level of RRM1 protein (P > 0.05). There was also no relationship between the expressions of ERCC1 and RRM1 proteins (P > 0.05). Conclusion: A low level of ERCC1 protein is more likely to be expressed in lung adenocarcinoma patients with EGFR mutation, who may benefit from the platinumbased chemotherapy. Copyright © 2013 by TUMOR.
